PMS2 and neoplasm: In December 2021, a kit for detecting deficient mismatch-repair (MMR) function that consists of 4 IHC test kits, each of which detects an MMR protein expressed in tumor tissue (MLH1, MSH2, MSH6, and PMS2), was approved as an in vitro diagnostic in Japan.